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Abstract 
Background and aims:  We investigated whether antioxidant therapy reduces pain and improves 
quality of life in patients with chronic pancreatitis. 
Methods:  We performed a double-blind, randomized controlled trial that compared the effects of 
antioxidant therapy with placebo in 70 patients with chronic pancreatitis. Patients provided 1 month of 
baseline data and were followed for 6 months while receiving either Antox version1.2 or matched 
placebo (2 tablets, 3 times daily). The primary analysis was baseline-adjusted change in pain score at 6 
months, assessed by an 11-point numerical rating scale. Secondary analyses included alternative 
analyses of clinic and diary pain scores, scores on quality of life tests (the EORTC-QLQ-C30, QLQ-
PAN28, EuroQOL EQ-5D, and EQ-VAS), levels of antioxidants, use of opiates, and adverse events. 
Analyses, reported by intention to treat, were prospectively protocol-defined. 
Results: After 6 months, pain scores reported to the clinic were reduced by 1.97 from baseline in the 
placebo group and by 2.33 in the antioxidant group but were similar between groups (-0.36, 95%CI: -
1.44 to 0.72, p=0.509).  Average daily pain scores from diaries were also similar (3.05 for the placebo 
group, 2.93 for the antioxidant group, a difference of 0.11; 95% CI, 1.05–0.82; P=0.808). Measures of 
quality of life were similar between groups, as was opiate use and numbers of hospital admissions and 
outpatient visits. Blood levels of vitamin C and E, -carotene, and selenium were significantly increased 
in the antioxidant group. 
Conclusions:  In patients with painful chronic pancreatitis of predominantly alcoholic origin, antioxidant 
therapy did not reduce pain or improve quality of life, despite causing a sustained increase in blood 
levels of antioxidants. 
Key words: randomized clinical trial; pancreatitis therapy; treatment response; efficacy 
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Introduction 
Chronic pancreatitis (CP) is an inflammatory condition of the pancreas characterized histologically by 
loss of normal pancreatic parenchymal architecture with varying degrees of fibrosis and inflammatory 
infiltrate1.   Clinically, chronic pancreatitis presents as a spectrum of disease characterized typically by 
chronic, unremitting and incapacitating abdominal pain together with varying features of pancreatic 
exocrine deficiency, which may lead to steatorrhea and manifestations of endocrine deficiency - 
diabetes mellitus2.   
To date there is no specific therapy for chronic pancreatitis.  Surgical interventions can be grouped as 
either resectional (removing the diseased head or entire gland) or drainage procedures3 (aimed at 
internal drainage of the dilated main pancreatic duct).  An alternative strategy involves thoracoscopic 
division of splanchnic nerves4.  Duct drainage can also be achieved endoscopically5.  None of these 
procedures are universally applicable to all patients with chronic pancreatitis and they carry varying 
degrees of risk of failure to achieve sustained pain relief. 
Seeking an alternative paradigm for chronic pancreatitis, Braganza and colleagues proposed that the 
disease arose as a result of pathological exposure of the acinar cells to short-lived oxygen free radicals 
– a process termed oxidative stress6.  A deficient free radical quenching system combined with excess 
free radical production led to cellular injury6.  Support for this hypothesis comes from several different 
sources: oxidative stress-response genes are up-regulated during experimental pancreatitis7; intra-vital 
microscopy using intra-acinar labeling has demonstrated short-lived oxidative bursts8; polymorphisms of 
the glutathione transferase gene are more prevalent in patients with chronic pancreatitis9; and, analysis 
of peripheral blood samples taken in clinical chronic pancreatitis have shown that anti-oxidants 
(inhibitors of the oxidative stress response), their precursors and co-factors in physiologic anti-oxidant 
pathways are depleted10.  In addition, there is elevation of peripheral blood markers of oxidative injury10.  
These clinical findings have been reproduced in Sowetan Africans (a group with a high incidence of 
chronic pancreatitis) suggesting that the results are independent of race and geography11. 
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Braganza and colleagues reasoned that exogenous supplementation with antioxidants or precursors for 
antioxidant pathways might help to reduce on-going acinar injury12.  From a series of exploratory studies 
they concluded that co-factors of the endogenous glutathione peroxidase pathway were key 
components for supplementation.  Selenium, vitamin C (ascorbic acid) and methionine were proposed 
as key antioxidants13.   
After two small randomized trials12,14 of selenium, -carotene, vitamins C & E and methionine-based 
antioxidant therapy reported a reduction in severity and frequency of episodes of pain in patients with 
recurrent and chronic  pancreatitis, a commercially available formulation, Antox (Pharma Nord, Morpeth, 
UK) was developed comprising vitamin C, vitamin E, -carotene, selenium and methionine.  Despite the 
obvious attraction of a pharmacologic intervention, antioxidant therapy for chronic pancreatitis has not 
become accepted as standard therapy.  The small, heterogeneous clinical trial base was thought to be 
a main reason for the lack of acceptance.  The recent publication of a report from Delhi in which 147 
patients were randomized to antioxidant therapy or placebo and which reported a main outcome 
measure of reduction in “painful days” might alter the position of equipoise15.  However, the Delhi study 
population comprised mainly young patients (age 29.6 ± 9.3 sd [standard deviation] years in the 
placebo group and 31.3 ± 11.4 sd years in the antioxidant group) in whom only 40 had alcohol related 
disease compared to 87 with idiopathic chronic pancreatitis.  Thus their recruited patients were very 
different to the older, alcohol-etiology dominant disease phenotype typically seen in Europe and the 
United States of America.  Furthermore, the study undertook no formal quality of life analysis. 
More than thirty years after the proposal of micronutrient antioxidant therapy for painful chronic 
pancreatitis the treatment remains only sporadically used and the optimal formulation of antioxidant 
regimen poorly understood.  Given the dearth of alternative therapies for patients with chronic 
pancreatitis there was a pressing case for a well-designed study to evaluate the effect of antioxidant 
therapy in a clearly defined population of patients. Given the fluctuating course of this disease, an 
assessment of the effect of intervention on both pain and quality of life was needed, providing the 
rationale for the ANTICIPATE trial.  
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Methods 
Study design  
A double-blind, placebo-controlled, single-centre randomised trial of Antox version 1.2 (Pharma Nord, 
Morpeth, UK) in patients with painful chronic pancreatitis. 
Setting 
Tertiary care academic medical centre. 
Hypotheses 
This trial tested the primary hypothesis that antioxidant therapy with antox version 1.2 would reduce 
pain in patients with painful chronic pancreatitis.  A secondary and supportive hypothesis was that 
treatment of these patients with Antox version 1.2 would improve quality of life as measured by 
validated questionnaires. 
Definitions of chronic pancreatitis and patient assessment protocols 
The terminology advocated by the Zurich international workshop was used to define chronic 
pancreatitis16.  The etiology of CP was categorized as alcoholic, hyperlipidemic, familial or idiopathic.  
Patients underwent a detailed clinical, radiological and biochemical baseline assessment prior to 
enrolment.  In addition to demographic data, specific information was collected on cigarette smoking, 
alcohol consumption, opiate intake and history of prior surgery or endoscopic intervention. After clinical 
assessment, full blood count, serum urea, electrolytes, biochemical liver function tests and lipid profiles 
were assessed together with fasting glucose, glycosylated hemoglobin and plasma CA 19-9. Baseline 
fasting anti-oxidant levels measured were: selenium, glutathione, vitamin C, vitamin E and β-carotene 
along with 9/11:9/12 linoleic acid ratio as a marker of free radical damage.  Baseline assessments 
further included: body mass index (BMI), diabetic status (according to WHO 2006 criteria)17 and fecal 
elastase (laboratory threshold of <200 μg/g stool diagnostic of exocrine insufficiency).  A qualified 
dietitian assessed nutritional status.  Imaging studies included: intravenous contrast-enhanced spiral 
contrast tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP) in selected 
patients and magnetic resonance pancreatography (MRCP).   ERCP/MRCP findings were graded from 
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1 to 4 (equivocal to marked) using the Cambridge criteria18.  Cross-sectional pancreatic imaging was 
reviewed at an appropriate hepato-pancreato-biliary (HPB) multi-disciplinary meeting. 
All patients received standard treatment for chronic pancreatitis (including analgesia as required) at the 
discretion of the clinical team providing care. All concurrent medication was recorded and non-protocol 
use of antioxidant therapy was specifically excluded.  
Inclusion criteria: 
These were: ability to give informed consent; age over 18 years; recent CT (ideally within 3 months of 
trial enrolment); either CT and/or ERCP or MRCP evidence of chronic pancreatitis; and a baseline daily 
pain score of 5 or greater on a numerical rating scale (NRS, scoring 0-10)19 for at least 7 days in a pre-
randomization run-in period of one month. 
Exclusion criteria: 
These were: inability to give informed consent, inability to comprehend or comply with the trial protocol, 
patients with chronic renal failure (with a creatinine clearance of less than 50 ml/minute), patients who 
were pregnant or lactating or who planned to become pregnant during the study period, those who were 
participating in another trial, patients who were already taking antioxidants and patients with a 
psychiatrist’s diagnosis of schizophrenia.  Patients with pancreatic cancer were also excluded. 
Randomization, stratification and blinding 
Computer generated randomization charts were produced by the statistician (JMM) who was not 
associated with the conduct of the study. Randomization was stratified by whether or not patients had 
undergone prior therapeutic pancreatic intervention (endoscopic, radiologic or surgical) and used a 
block size of four. Randomization charts were administered by the hospital trial pharmacy in a process 
ensuring concealed allocation. To provide double-blinding, drug and placebo were supplied by 
pharmacy as yellow, ovoid, compressed, film-coated tablets of similar appearance in sealed packages. 
Thus clinicians were separated from the randomization process and remained blind to the treatment 
allocated to patients. Similarly, patients remained blind to the treatment allocated.  
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Unblinding and withdrawal 
 In an emergency, treatment allocation could be unblinded at the request of the clinician providing care. 
Patients could withdraw from the trial at any point without alteration in standard care. The patient could 
be withdrawn if their attending clinician judged that circumstances arose that were detrimental to the 
individual.  
Study medication 
All patients recruited to the study received antioxidant therapy or matched placebo for the 6 month 
period of the trial.  Trial packs contained 600 tablets as 20 blister strips of 30 Antox version 1.2 tablets 
or matched placebo, two tablets taken three times daily.  Antioxidant supplementation contained active 
ingredients: 38.5 mg selenium yeast of which 50μg was l-selenomethionine, 113.4 mg d--tocopherol 
acetate, 126.3 mg ascorbic acid and 480 mg l-methionine together with secondary ingredients: 285.6 
mg microcrystalline cellulose, 14.0 mg croscarmellose sodium, 7.0 mg colloidal anhydrous silica and 3.0 
mg magnesium stearate.  The coating included 4.2 mg β carotene.  Placebo supplementation 
contained: 657.9 mg microcrystalline cellulose, 73.3 mg croscarmellose sodium, 15.0 mg colloidal 
anhydrous silica and 3.7 mg magnesium stearate per tablet.  
Primary Outcome Measure 
Change in clinic pain score from baseline to 6 months. The primary analysis compared the change in 
pain between groups, analysed by Student’s t-test. 
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Secondary Outcome Measures 
These included: clinic and diary pain scores as repeated measures; diary recorded pain analysed as the 
average of daily scores over 6 months; Brief Pain Inventory (BPI) scores analysed as repeated 
measures; quality of life scores analysed as repeated measures (EORTC-QLQC20, QLQ-PAN26, 
EuroQOL21 EQ-5D and EQ-VAS); change in antioxidant levels from baseline to 6 months; opiate usage 
(defined as morphine equivalents) analysed as repeated measures; rates of hospital admission for 
pancreatitis-related exacerbations or complications; and, rates of treatment-related side effects and 
complications.  
 
Assessment of outcome measures and monitoring during study 
The primary outcome measure was clinic pain score recorded using an 11-point numerical pain rating 
scale (NRS) previously validated for the assessment of chronic pain19.  Patients were shown the scale 
by the research fellow during the consultation and asked to indicate where they felt their pain score 
should be marked. The same 11-point numerical pain rating scale was used by patients to record pain 
in a daily pain diary: this diary was maintained by the patients.  Diary records were aggregated to 
average monthly scores from baseline (the month before randomization) to month 6. Clinic 
assessments (at 0, 2, 4 and 6 months) included:  pain NRS scores, record of adverse events, the Brief 
Pain Inventory, disease specific quality of life measures: EORTC QLQ-C30 (score 30 to 120) and QLQ-
PAN28 (score 26 to 112)20 and generic measures: EuroQOL EQ-5D (score 0 to 1, negative scores 
possible) and EQ-VAS (Visual Analog Score, score 0 to 100)21; record of opiate use and hospitalization.  
Blood antioxidant levels were measured at baseline, study mid-point and at 6 months.  Questionnaires 
were administered by the trial clinical research fellow (NS) in an outpatient clinic setting. 
Assessment of compliance was not formally tested in this pragmatic, outpatient based study design.  
However, completion of pain diaries and measurement of antioxidant levels were accepted as surrogate 
markers of compliance 
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Safety evaluation and reporting of adverse events 
Patients were monitored for treatment-related side effects and complications. Adverse events were 
recorded, assessed for severity and attribution, and reported in line with European Directive 
2001/20/EC. Specific pancreatitis-related complications included hospital admission with acute 
exacerbation of chronic pancreatitis or for pain control (defined from hospital discharge notes). 
Complications such as pancreatic pseudocyst or pancreatic abscess were defined according to the 
1992 Atlanta consensus conference criteria22. 
Statistical Analysis 
Sample size calculation. In a previously published study, anti-oxidant therapy was associated with a 12 
point reduction in pain on a 100 point VAS (visual analog scale)23.  The variance structure for a change 
in pain score in a cohort of patients with chronic pancreatitis was unknown, typical published values for 
VAS change scores in other populations suggested a standard deviation of 15 points.  A sample size 
calculation based on a 1.2 point change in pain on a numerical rating scale (0-10, 11 points) with a 
standard deviation of 1.5 points, with 80% power and alpha at 0.05 required 26 patients in each arm of 
the trial.  Allowing for 10% loss to follow-up, the trial aimed to recruit 57 patients.  At an interim 
inspection, the independent trial steering committee advised that enrolment be increased to 
approximately 90 patients to accommodate effects of withdrawal or loss to follow-up. 
Descriptive and analytic statistics. Descriptive statistics (continuous: mean and standard deviation; 
binary: proportion; categorical: median and range) were calculated for study variables. Differences 
between treatment groups for endpoint and change scores were analyzed using the unpaired Student t 
test; repeated measures analyses of variance were covariate-adjusted for the baseline measure and 
trial strata, matching the trial design; proportions were analyzed using exact tests; individual items of the 
EORTC questionnaires were analyzed using the Mann Whitney U test. EORTC total and sub-domain 
scores were analyzed as continuous measures consistent with the assumptions underpinning 
aggregation of responses to individual questions. Diary pain scores were averaged monthly and over 
the entire 6 month follow-up period. Since hospital admission data are typically highly skewed, 
estimates of differences used bootstrapping with 10,000 samples. All analyses were conducted by 
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intention to treat and to protocol. SPSS 19 (IBM, New York, USA) was used for statistical analysis. 
Ethical Approvals 
The study protocol was approved by the North-West Regional Ethical committee (MREC, 
07/MRE08/13) and the United Kingdom Medicines & Health products Regulatory Agency (MHRA, 2006-
006958-10).  Study oversight was provided by an independent trial steering committee. 
The study was registered with the International Standard Randomized Controlled Trial database 
(ISRCTN-21047731).  Trial reporting follows CONSORT guidelines (Figure 1). 
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RESULTS 
In total, 356 patients with CP were assessed during the enrolment period from February 2008 to August 
2009, of whom 92 fulfilled the inclusion criteria and agreed to participate in the trial.  
Completeness of follow-up 
One patient randomized to placebo withdrew and did not receive intervention.  Fifteen patients withdrew 
within the first two months of enrolment.  Six further patients were lost to follow-up after completion of 
the first 2 months but before the 6 month appointment.  No patients were withdrawn by the 
investigators.  Seventy patients completed follow-up to six months and are reported in the analysis (see 
Figure 1). The study was closed to new recruitment at the end of August 2009 with a subsequent 6 
month data maturation phase to allow for completion of data collection.   
Baseline comparability 
Treatment and placebo groups were similar at baseline with respect to age, gender, duration of disease, 
previous intervention, etiology of chronic pancreatitis, pancreatic exocrine function, alcohol and 
cigarette consumption, BMI, diabetes and opiate use (Table 1). 
Response to treatment 
Primary outcome measure.  
NRS pain scores reported on the day of clinic visits are shown in Figure 2. Analyses of change scores 
show a reduction in pain in both groups from baseline to 6 months, but no statistically significant 
difference in reduction (Placebo: -1.97, Antioxidant: -2.33, Difference: -0.36, , 95%CI: -1.44 to 0.72, 
p=0.509, see Table 2).   
Re-analysis of clinic pain scores using repeated measures ANOVA supported the primary analysis of no 
difference in pain between antioxidant and placebo groups (-0.07, 95%CI: -0.97 to 0.83, p=0.875;Table 
2 and Figure 2).   
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Secondary outcome measures.  
Analysis of diary data found no difference in pain between antioxidant and placebo groups as a change 
score (-0.34, 95%CI: -0.98 to 0.31, p=0.302), using repeated measures ANOVA (0.04, 95%CI: -0.61 to 
0.52, p=0.878) or daily average score (-0.11, 95%CI: -1.05 to 0.82, p=0.808), supporting the primary 
analysis (Table 2 and Figure 3).  
The Brief Pain Inventory addresses the location of disease specific pain, assessing worst, least and 
average levels of pain in the preceding week: analyses of these three measures similarly found no 
difference in pain between groups (Table 2). 
Quality of life scores were analysed as repeated measures.  There was no evidence of differences in 
EORTC QLQ-C30, PAN28, EuroQOL EQ-5D or EQ-VAS as summary scores (Table 2).  Analysis of 
individual questions and sub-domains of both QLQ-PAN28 and QLQ-C30 at six months identified no 
statistically significant differences. 
Need for supportive care.  
Average opiate usage was similar between groups and consistent over the 6 month period of follow-up.  
Similarly, pancreatitis-related hospital inpatient stays and outpatient clinic attendances were similar 
between groups (Table 2).   
Antioxidant levels 
Serum/plasma antioxidant levels (vitamin C, vitamin E, -carotene, selenium) were increased 
significantly at 6 months in patients receiving active treatment, while placebo levels remained similar to 
baseline (Table 3). Measures of whole blood glutathione were not modified substantially within the trial. 
Haematological and biochemical levels  
Across a wide range of haematological and biochemical values, no significant differences emerged 
between groups during treatment (Table 3). 
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Adverse events 
A total of 9 adverse events were recorded (1 placebo and 8 antioxidant).  Of these, 7 events were mild 
and related to bad taste and heartburn with nausea.  One moderately severe adverse event in the 
antioxidant group related to increased frequency of stool and occasional diarrhoea.  The other 
moderately severe adverse event in the antioxidant group was a patient hospitalized with convulsions 
due to hepatic encephalopathy.  Apart from this last individual the other 8 patients reporting adverse 
events withdrew within the first few months of follow-up. 
Requirement for alternative interventions during the study 
No patients underwent surgery for chronic pancreatitis during the course of the study. Two patients in 
the placebo group underwent endoscopic intervention: one underwent pancreatic duct stenting and the 
other underwent endoscopic drainage of a pancreatic pseudocyst.  This latter individual was one of the 
patients who withdrew from the study. One further patient in the placebo arm underwent an urgent 
laparotomy for visceral perforation, temporarily withdrew from the study during the post-operative 
period, but then re-entered and completed his allocated intervention. 
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DISCUSSION 
This trial addresses the question of the value of antioxidant therapy for patients with chronic 
pancreatitis. The answer is important since the health care burden of chronic pancreatitis is 
considerable and patients with this disease suffer from sustained distressing symptoms of which pain is 
the dominant feature.  A pharmacologic intervention is attractive as it obviates the need for surgical or 
endoscopic interventions (neither of which is consistently beneficial in reducing pain). 
Emphasis was placed within the trial design on the definition of the study population.  The aim was to 
focus on those patients most typically seen in a European or North American Gastroenterology clinic in 
whom alcohol would be the predominant etiologic agent.  Radiologic evidence of chronic pancreatitis 
was mandatory both to help diagnose and categorise chronic pancreatitis and to help exclude other 
conditions such as pancreatic cancer which can mimic chronic pancreatitis. In keeping with current 
specialist pancreatic practice, not all patients underwent ERCP and no patients underwent diagnostic 
ERCP.  In United Kingdom practice, interventional tests of pancreatic endocrine function are not 
widespread and standard practice includes measurement of faecal elastase.  
A second aspect of the study design is the selection of patients with stable but symptomatic disease.  A 
daily NRS pain score of 5 or greater on at least 7 days during the one month pre-randomization run-in 
period was required for a patient to be enrolled.  Conduct of the study at a single center might 
compromise the generalizability of the findings.  However, the spectrum of disease was typical for a 
tertiary clinic and European or North American population, and use of a single researcher for clinic 
assessment facilitated consistent measurement of pain in patients. A further important issue is that of 
power.  Post hoc re-examination of the variance in pain numerical rating scale scores from our own data 
suggests a more conservative standard deviation of 2 points rather than 1.5.  A change of 1.2 points (or 
an effect size of 0.6) suggests a planned recruitment of 90 subjects and since we report only 70 patients 
there might be an argument that we cannot exclude type II error at conventional levels. Further, 
differences in assessment and reporting of pain in clinical studies of chronic pancreatitis (“painful days” 
used in the Bhardwaj study)15 and also in other chronic disease states can make comparison between 
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studies difficult19.  Thus it would be wise to accept that the possibility of type II error has not 
categorically been rejected. 
The duration of intervention, use of a placebo arm and stratification are also features with potentially 
critical influence on trial outcome.  A six-month follow-up period was thought to be of sufficient duration 
to be representative, allowing sufficient time for selenium levels to attain plateau but avoiding the 
potential ethical difficulties of giving patients placebo treatment for prolonged periods.  A placebo arm 
was felt to be justifiable and necessary given the general lack of acceptance of antioxidant therapy in 
chronic pancreatitis.  Patients were stratified by prior pancreatic intervention to design out an important 
potential confounding variable. It might be argued that end-stage pancreatic disease is another 
important confounder although difficult to stratify within the randomisation when occurring in small 
numbers.  Proxied by faecal elastase measurement, randomisation allocated these patients similarly to 
treatment and placebo groups (see Table 1). 
The primary endpoint was selected as the baseline-adjusted change in clinic pain score and supportive 
secondary endpoints included other analyses and assessments of pain, as well as quality of life using 
separate, validated assessment tools.   
With these design features in mind, the present study represents a well-designed trial conducted in a 
relevant and well-characterised study population.  The recruitment process delivered two groups similar 
in terms of age, gender, disease profile and duration, etiology of CP and opiate use (Table 1). 
Compliance with study drug use was not formally verified although plasma antioxidant levels in patients 
demonstrate consistent and considerable treatment effect consistent with compliance. Similarly, the 70 
patients completing the study provided complete diary data suggesting considerable engagement with 
the study aims. 
There was no significant difference between groups in any outcome measured other than change in 
antioxidant levels (Tables 2 and 3).  Analyses of change of pain scores show a reduction in pain in both 
groups from baseline to 6 months but no significant difference between groups (Figure 2).  These 
findings may help explain why individual patients and inadequately controlled studies might attribute 
benefit to antioxidant therapy, if receiving treatment in response to an episode of pain.  Assessment of 
quality of life was necessary since pain has a diffuse impact on multiple aspects of individual 
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functioning.  Comprehensive quality of life assessment showed that there were no reported benefits 
from antioxidant treatment in any of the domains assessed.   
Of 356 patients assessed for eligibility, 92 patients entered the trial.  The main reasons for exclusion 
were either that patients had already been initiated on, or were not eligible for, antioxidant therapy 
under normal clinical care.  Thus there were no selection effects limiting the disease spectrum of 
patients participating in the trial. Patient decisions to withdraw or not to attend follow-up clinics led to 22 
individuals being were lost to the analysis.  Withdrawals were similar, by treatment allocation, in age, 
gender and baseline pain scores.  
A previous trial of antioxidant treatment for chronic pancreatitis took as its primary definition: ‘painful 
days per month’ recorded within pain diaries15.  This assessment was not performed directly in the 
present study but could be approximated with the data generated within this trial by setting a threshold 
on the diary VAS pain score qualifying as a “painful day”.  The threshold was varied from 1 to 10: at no 
threshold was there a significant difference in days free from pain comparing antioxidant and placebo 
(Figure 4). 
Previous studies of antioxidant therapy in chronic pancreatitis can be dichotomized into several older, 
smaller trials12, 14, 23, and one more recent, well-designed larger trial15.  Interpretation of the small trials is 
problematic due to their poorly characterized and heterogeneous patient populations (not all patients in 
the early Manchester studies had chronic pancreatitis) as well as non-standardised reporting of 
endpoints.  In contrast, Bhardwaj and colleagues reported the largest randomized trial of antioxidant 
therapy in chronic pancreatitis with similar assessment and work-up protocols to the present study.  The 
principle conclusion of Bhardwaj that “antioxidant supplementation was effective in relieving pain in 
patients with chronic pancreatitis” is in direct contrast to the findings of the present trial. A potential 
reason for this discrepancy could lie in differences in the patient cohorts recruited: the mean age was 
lower: 31 years compared to 50 years in the present study.  Similarly, etiology differed: 31% vs. 72% of 
predominantly alcoholic origin; alcohol consumption was almost two times higher in the present study 
while Bhardwaj report a greater proportion of patients with malnutrition.  Further, in the Bhardwaj study 
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there were 36 (28%) cigarette smokers compared to 56 (80%) in the present study.  In addition to these 
clinical and demographic differences, there is a difference in the morphological disease profile: 
Bhardwaj reports that 79% of patients had evidence of a dilated main pancreatic duct compared to 57% 
in the present study.  Finally the composition and dose of antioxidant constituents differs between the 
trials. While both study cohorts of patients might fulfil the broad criteria for definition of chronic 
pancreatitis, the present study provides a population of older, alcohol-etiology dominant disease that is 
typical of the clinical phenotype seen in Europe and North America.  Interestingly, Bhardwaj reports no 
benefit (of reduced pain) in the sub-group of patients with alcoholic aetiology (antioxidant 3.7 painful 
days vs placebo 4.2 painful days; p=0.61), consistent with the general finding of the present study. 
Different methods of assessment might account for some discrepancy: the primary endpoint of “painful 
days” utilized by the Bhardwaj study was based solely on patient diary records.  In the present study, a 
clinic-based estimate of pain using a validated numerical rating scale was the primary endpoint but was 
contextualised by diary-based pain scores and quality of life assessment.  
Since there are some differences both in inclusion and assessment, replication of studies (with an 
extended range of outcomes drawn from both studies) may be required in order to provide definitive 
resolution of uncertainties. 
How might the apparent lack of effect of antioxidant therapy be reconciled with the genetic evidence of 
up-regulation of oxidative stress response genes and the cell biological evidence of oxidative stress?  A 
potentially important mechanistic insight from the present study is that exogenous dietary 
supplementation – in pharmacological concentrations – may cause a significant elevation in circulating 
antioxidant levels but not have an impact on symptoms.  Thus, at the point of presentation with 
symptoms, with evidence of likely irreversible pancreatic parenchymal and functional alteration, the 
potential time-point for disease modification by exogenous antioxidant supplementation may be past. 
In summary, this paper reports a randomized controlled trial of the compound antioxidant therapy Antox 
version 1.2 in a well-characterised population of patients with chronic pancreatitis with comparable 
clinical characteristics at baseline.  The primary outcome measure of NRS pain scores reported on the 
day of clinic visits shows a reduction in pain in both groups from baseline to 6 months, but no 
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statistically significant difference in reduction (Placebo: -1.97, Antioxidant: -2.33, Difference: -0.36, 
p=0.509).    Similarly there was no difference in diary-based visual analogue scores, Brief Pain 
Inventory or quality of life using validated questionnaires.  
Despite the lack of a strong evidence base, micronutrient antioxidant therapy has for over 30 years 
been regarded as an alternative paradigm for chronic pancreatitis and continues to be strongly 
advocated by its supporters.  In this regard the importance of the present study is that when patients 
present with abdominal pain, with clinical, radiological and physiological evidence of chronic 
pancreatitis, micronutrient antioxidant therapy with Antox is not likely to contribute to any reduction in 
pain or improvement in quality of life.   
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Table 1. Baseline Demographic and Clinical Parameters:  
Antioxidant and Placebo Groups 
 
 
 Placebo (37) Antioxidant (33) p 
Age at enrolment (y) 50±9 49.8±12.7 0.96 
Gender male:female 27:10 23:10 0.80 
Disease duration (y) 4.9±4.3 4.2±2.4 0.36 
Clinic NRS (SD) 5.0±1.6 5.2±1.6 0.36 
Previous intervention yes:no 20:17 18:15 1.00 
Etiology alcohol:idiopathic 27:10 24:9 1.00 
ER (MR) CP*   0.19 
Faecal elastase (μg/g) 192±198 221±198 0.56 
Faecal elastase <15 (μg/g) 7 8  
 
Alcohol (g/d) 247±202 222±123 0.59 
Cigarette smoker: yes:no 28:9 28:5 0.38 
Cigarettes (/d) 22±8 21±11 0.83 
BMI (kg/m) 22.7±4.5 23.2±3.8 0.62 
Diabetes mellitus: yes:no 11:26 10:23 1.00 
Morphine equivalent (mg/d) 91±105 85±114 0.84 
* Data available for 24 placebo and 14 antioxidant receiving patients, d=day, 
µg=micro gram, kg= kilogram, g=gram, y=years. 
 
Equivocal 0 (0%) 1 (6.3%)  
Mild 4 (16.7%) 4 (25.0%)  
Moderate 15 (62.5%) 9 (56.3%)  
Marked 5 (20.8%) 2 (12.5%)  
CT   0.13 
Calcification 12 (32.4%) 18 (54.5%)  
Dilated pancreatic duct 2 (5.4%) 2 (6.1%)  
Calcification and dilated 
pancreatic duct 
23 (62.2%) 13 (39.4%)  
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Table 2. Analysis of response to treatment 
 
 
 Placebo 
[P=37] 
Antioxidant  
[A=33] 
 
[A-P] (95%CI) 
 
p 
Pain scores     
Clinic NRS [change] (SD)1 -1.97 (2.46) -2.33 (2.09)  -0.36 (-1.44 to 0.72) 0.509 
Clinic NRS [R-M]2 3.09 3.02  -0.07 (-0.97 to 0.83) 0.875 
Diary NRS [change] (SD)3 -0.80 (1.35) -1.14 (1.35)  -0.34 (-0.98 to 0.31) 0.302 
Diary NRS [R-M]4 2.97 3.02  0.04 (-0.61 to 0.52) 0.878 
Diary NRS [average] (SD)5  3.05 (1.96)  2.93 (1.96)  -0.11 (-1.05 to 0.82) 0.808 
BPI [worst, R-M]2,6 4.16 4.47  0.31 (-0.99 to 01.62) 0.632 
BPI [least, R-M]2,6 1.83 1.79  -0.04 (-0.77 to 0.69) 0.913 
BPI [average, R-M]2,6 3.30 3.21  -0.09 (-1.00 to 0.84) 0.854 
Quality of life measures     
EORTC QLQ-C302 65.2 62.1  -3.3 (-9.4 to 2.8) 0.283 
Physical functioning (Q. 1-5) 9.07 8.08  -0.99 (-2.20 to 0.22) 0.106 
Role functioning (Q. 6,7) 4.27 4.19  -0.08 (-0.85 to 0.70) 0.844 
Cognitive functioning (Q. 20,25) 3.88 3.53  -0.35 (-0.89 to 0.20) 0.208 
Emotional functioning (Q. 21-24) 9.05 8.80  -0.25 (-1.46 to 0.97) 0.688 
Social functioning (Q. 26,27) 4.18 4.02  -0.16 (-0.88 to 0.57) 0.667 
Overall global quality of life (Q. 29,30) 8.15 8.53  -0.38 (-0.88 to 1.64) 0.548 
EORTC QLQ-PAN282 59.9 55.8  -4.1 (-8.5 to 0.2) 0.060 
Pancreatic pain (Q. 31,33,35) 6.65 6.57  -0.08 (-1.05 to 0.90) 0.874 
EQ-5D2 0.51 0.55  0.04 (-0.10 to 0.19) 0.559 
EQ-VAS2 56.6 58.9  2.3 (-6.5 to 11.1) 0.601 
Supportive care     
Morphine equivalent (mg/day)2 92.7 79.0  -13.7 (-38.0 to 10.6) 0.266 
Hospital Inpatients (days)7  4.00 (8.11)  3.94 (7.75)  -0.06 (-3.80 to 3.53) - 
Hospital outpatient visits7   1.32 (1.25)  1.12 (1.27)  -0.20 (-0.78 to 0.38) - 
1 Change score (6 months – baseline) 
2 Repeated measures model: estimated mean of observations at 2, 4 and 6 months 
3 Change score (month 6 – month pre baseline) 
4 Repeated measures model: estimated mean of observations for months 1 to 6 
5 Average daily pain score during months 1 to 6. 
6 Brief Pain Inventory: average level of pain in the previous week 
7 Bootstrapped estimate of difference and confidence interval 
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Table 3. Changes in antioxidant, haematological and biochemical levels 
 
 
 Placebo 
[P=37] 
Antioxidant  
[A=33] [A-P] (95%CI) P 
Antioxidant levels1     
Vitamin C (mg/mL)  -0.70 (5.15)  8.34 (8.76)  9.04 (5.54 to 12.54) <0.001 
Vitamin E1 (mg/mL) 1  -1.88 (10.02)  7.42 (17.95)  9.30 (2.20 to 16.40) <0.011 
β-carotene (mg/mL)1  7.85 (34.05)  62.56 (125.68)  54.72 (8.83 to 100.51) 0.021 
Selenium (µmol/L)1  0.92 (12.39)  42.73 (32.27)  41.81 (29.73 to 53.88) <0.001 
WGSH1  -3.72 (176.91) -32.38 (251.29)  -28.65 (-132.98 to 75.68) 0.593 
WGSH-Hb1 -0.0028 (1.1783) 0.0212 (1.1671)  0.0240 (-0.5450 to 0.5929) 0.933 
WGSH-RBC1 -86.94 (364.50) -25.25 (377.97)  61.69 (-119.88 to 243.26) 0.500 
Biochemistry values11     
Hemoglobin (gm/dL) -0.211 (1.375) -0.118 (1.305)  -0.093 (-0.732 to 0.547) 0.773 
Glycosylated hemoglobin (%) -0.084 (1.015)  0.030 (0.801)  -0.114 (-0.548 to 0.320) 0.602 
White cell count (109/l) -0.611 (2.331) -0.570 (2.382)  -0.041 (-1.168 to 1.086) 0.942 
Fasting blood glucose (mmol/L)  0.551 (2.671)  0.209 (2.988)  0.342 (-1.017 to 1.702) 0.617 
Total cholesterol(mmol/L)  0.095 (0.953)  0.009 (1.387)  0.086 (-0.491 to 0.662) 0.767 
HDL(mmol/L)  0.037 (0.241)  0.038 (0.388)  -0.001 (-0.158 to 0.157) 0.994 
Triglycerides (mmol/L) -0.051 (0.753)  0.155 (2.746)  -0.205 (-1.206 to 0.796) 0.680 
linoleic acid 9,11 (µmol/l)1  0.281 (5.709)  0.743 (6.046)  0.462 (-2.353 to 3.277) 0.744 
linoleic acid 9,12 (µmol/l)1  -13.3 (242.6)  3.6 (238.4)  16.9 (-98.0 to 131.8) 0.770 
linoleic acid 9,11:9,12(%)1  0.126 (0.537)  0.092 (0.614)  -0.034 (-0.311 to 0.243) 0.808 
Calcium (mmol/L) -0.021 (0.109) -0.046 (0.093)  0.025 (-0.023 to 0.073) 0.299 
Magnesium (mmol/L)  0.009 (0.092)  0.000 (0.090)  0.009 (-0.035 to 0.052) 0.683 
Bilirubin(µmol/L) -0.110 (5.924) -0.150 (2.959)  0.043 (-2.165 to 2.252) 0.969 
Alkaline phosphatase (µL)  22.8 (228.8)  17.2 (63.2)  5.6 (-73.5 to 84.7) 0.888 
Total protein (g/L)  0.00 (6.616)  -1.70 (5.714)  1.70 (-1.24 to 4.64) 0.254 
Albumin (g/L)  1.51 (4.513)  0.85 (3.429)  0.66 (-1.24 to 2.57) 0.487 
CA 19-9 (mU/ml)  1.70 (15.772)  0.21 (9.343)  1.49 (-4.63 to 7.61) 0.628 
CRP (g/L)  -7.27 (30.51)  -5.18 (28.01)  -2.09 (-16.05 to 11.87) 0.766 
1 Unpaired t test on change score (6 month – baseline) values , CRP= C reactive protein, HDL= High density lipoprotein, 
µL=microlitre, mmol=milimol, µmol=micromol, g=gram, WGSH= Whole blood glutathione, Rbc=red blood cell, Hb=hemoglobin 
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Figure 2: Clinic NRS Pain Scores 
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Figure 3: Diary NRS Pain Scores 
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Figure 4: Percentage of days free from pain by pain threshold 
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